Topische Langzeittherapie der Psoriasis mit Vitamin‐D₃‐Analoga, Kortikosteroiden und deren Kombinationen: Positionspapier zu Evidenz und praktischer Anwendung

Abstract

ZusammenfassungHintergrund: Aktuelle Daten aus der Versorgungsforschung zeigen, dass Vitamin-D 3 -Analoga, Kortikosteroide und deren fixe Kombinationen in der topischen Langzeittherapie der Psoriasis sehr unterschiedlich eingesetzt werden. Praxisempfehlungen: Patienten müssen aktiv in die Wahl der Therapie, der Grundlage und der Anwendungsweise einbezogen werden. In der Praxis haben sich neben der Langzeittherapie mit der Fixkombination auch andere Therapieschemata unter Einbeziehung der Calcipotriol-Monotherapie bewährt. Aufgrund des guten Nutzen-Risiko-Profils in Studien zur Erhaltungstherapie und aufgrund der höheren Wirtschaftlichkeit ist im Anschluss an die Initialtherapie eine 1-bis 2-mal wöchentliche Applikation der Fixkombination zu empfehlen. Zielsetzung SummaryBackground: Current data from daily practice show that vitamin D 3 analogues, corticosteroids and their fixed combination products are used heterogeneously for topical long-term treatment of psoriasis.

Effectiveness and tolerability of calcipotriol/betamethasone aerosol foam in patients with psoriasis vulgaris in real‐life setting: A prospective, noninterventional, multicenter observational study in Austria

“…9 The aerosol foam appears to reach its maximum effect after an initial treatment of 4 weeks, which should be optimally maintained in a continuation therapy with prolonged dose intervals. 10,11 The aim of this noninterventional study was to investigate the effectiveness and tolerability of Cal/BD aerosol foam in a real-life setting during and after 4 weeks of therapy to optimize practical recommendations.…”

“…In Austria, approval was granted by the Federal Office for Safety in Health Care (Bundesamt für Sicherheit im Gesundheitswesen—BASG) on 30 May 2016 9 . The aerosol foam appears to reach its maximum effect after an initial treatment of 4 weeks, which should be optimally maintained in a continuation therapy with prolonged dose intervals 10,11 …”

PSO-LONG: Design of a Novel, 12-Month Clinical Trial of Topical, Proactive Maintenance with Twice-Weekly Cal/BD Foam in Psoriasis

“…Long-term studies of topical agents for the treatment of psoriasis that are currently available have certain limitations. These include, but are not limited to, the nature of open-label studies, relatively small patient populations, the absence of a placebo arm, and the reliance on self-reported patient measures as the final study outcomes [ 30 – 32 ]. Moreover, the studies may be characterized by inadequate safety assessments, nonstandardized treatment dosing and administration, and lack of consensus on definitions for treatment success and endpoints.…”

“…Moreover, the studies may be characterized by inadequate safety assessments, nonstandardized treatment dosing and administration, and lack of consensus on definitions for treatment success and endpoints. A recent review and position statement on the treatment of psoriasis with vitamin D 3 analogues, corticosteroids, and compound formulations revealed that few, large, long-term, randomized, blinded clinical trials have been conducted [ 30 ].…”